Sihuan Pharmaceutical Holdings Group Ltd. has announced that its innovation Xuanzhu Biopharmaceutical Co., Ltd., a pharmaceutical platform company, will acquire 100% of the shares of Beijing Combio Pharmaceutical. The acquisition of Combio Pharmaceutical by Xuanzhu Biopharm has fully expanded the depth and breadth of the company's innovative drug product pipeline, and introduced the highly potential "Mab Edit" (antibody editing) and "Mebs-Ig" (antibody editing bispecific antibodies), two major antibody technology platforms. Xuanzhu Biopharm has a total of 14 innovative product projects under research, and the pipeline covers multiple fields such as oncology, metabolic disorders and infectious diseases, many of which have entered the late clinical stage. The leading product Birociclib has successfully carried out clinical trials on 3 indications and is a CDK4/6 inhibitor for advanced breast cancer. Among them, the single-drug treatment of Birociclib is already in phase II clinical trials, and if relevant requirements are met, phase III clinical trials can be skipped directly for marketing. On the other hand, Combio Pharmaceutical product pipeline already has 12 products under development, of which KM257/252 is a bispecific antibody drug for cholangiocarcinoma, breast cancer, gastroesophageal cancer, etc.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!